Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-11-26 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
上海荣正企业咨询服务（集团）股份有限公司 关于广东永顺生物制药股份有限公司 2024年股权激励计划（草案）之 独立财务顾问报告
Regulatory Filings
2024-11-26 Chinese
监事会关于公司2024年股权激励计划（草案）的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2024 equity incentive plan draft. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and procedural correctness. It does not contain financial statements or results, nor is it an announcement of voting results or a proxy solicitation. It is a regulatory compliance and internal governance related document concerning an equity incentive plan. Given the content and length (1752 characters), it is not a full report but a regulatory announcement or compliance opinion. This fits best under Regulatory Filings (RNS), as it does not match other specific categories like Management Reports or Capital/Financing Updates.
2024-11-26 Chinese
第五届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of several proposals related to the 2024 equity incentive plan, core employee recognition, and related management measures. The document does not contain financial statements or detailed financial data but rather the results of board-level decisions and approvals. It also references that the detailed plans and disclosures are published separately on the Beijing Stock Exchange information platform. The document length is 2657 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement of board resolutions and meeting outcomes without substantive financial data or report content.
2024-11-26 Chinese
第五届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fifth board of directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting's attendance, the agenda items discussed, voting results, and references to further disclosures on the stock exchange platform. The content focuses on board decisions, including approval of a 2024 equity incentive plan and related matters, and the scheduling of a shareholders' meeting. There are no financial statements or detailed financial performance data presented. The document is not a full report but an official announcement of board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive board meeting details rather than just a brief report publication notice, so it is not an RPA. Hence, the classification is MANG with high confidence.
2024-11-26 Chinese
2024年股权激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation and assessment of a 2024 equity incentive plan by Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, indicators, procedures, and management of the assessment related to the equity incentive plan. It references company governance, board responsibilities, and shareholder approval. The document is not a financial report, earnings release, or audit report. It is a detailed governance-related document about the company's internal rules and procedures for managing an equity incentive plan, which falls under governance information. The document length is 3398 characters, which is substantive and not a mere announcement or certification. Therefore, the best fitting category is Governance Information (CGR).
2024-11-26 Chinese
广东君信经纶君厚律师事务所关于广东永顺生物制药股份有限公司 2024 年股权激励计划（草案）的法律意见书
Regulatory Filings
2024-11-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.